Related Experiment Video
Updated: Jun 4, 2026
09:00
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction
J M Diamond1, S M Kawut, D J Lederer
1Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. joshua.diamond@uphs.upenn.edu
Summary
Elevated Clara cell secretory protein (CC16) levels after lung transplantation indicate epithelial injury and are linked to a higher risk of primary graft dysfunction (PGD). This finding may improve early PGD detection.
Area of Science:
- Pulmonology
- Transplant Surgery
- Biomarker Research
Background:
- Primary graft dysfunction (PGD) significantly impacts lung transplant outcomes.
- Clara cell secretory protein (CC16) is a potential biomarker for lung epithelial cell injury.
Purpose of the Study:
- To investigate the association between plasma CC16 levels and the development of PGD post-lung transplantation.
- To determine if CC16 can serve as an early predictor of PGD.
Main Methods:
- Prospective cohort study of 104 lung transplant recipients.
- Measurement of plasma CC16 levels at pretransplant, 6 hours, and 24 hours posttransplant.
- Logistic regression analysis to assess the association between CC16 and grade 3 PGD within 72 hours.
Main Results:
- 28% of patients developed grade 3 PGD.
- Significantly higher median CC16 levels were observed 6 hours posttransplant in patients who developed PGD (13.8 ng/mL) compared to those who did not (8.2 ng/mL).
- Elevated CC16 levels at 6 hours posttransplant were associated with increased odds of PGD.
Conclusions:
- Elevated plasma CC16 levels post-lung transplantation are associated with an increased risk of developing primary graft dysfunction.
- CC16 may indicate airway epithelial damage or altered alveolar permeability due to ischemia-reperfusion injury.
- CC16 shows promise as an early predictive biomarker for PGD in lung transplant recipients.
